Literature DB >> 3863691

Values of CA 19-9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor.

M Tatsuta, H Yamamura, H Iishi, M Ichii, S Noguchi, R Yamamoto, S Okuda.   

Abstract

The diagnostic accuracy of the measurement of CA 19-9 in the serum, pure pancreatic juice, and aspirated pancreatic fluid in the diagnosis of pancreatic tumors was assessed in 32 patients with malignant pancreatic tumors and 19 patients with pancreatitis. Pure pancreatic juice was collected from the pancreatic duct by endoscopic cannulation with a duodenofiberscope after intravenous administration of secretin. Pancreatic material was obtained by percutaneous fine-needle aspiration biopsy under ultrasonic guidance. Abnormally high CA 19-9 levels in the serum were significantly more frequent in patients with malignant pancreatic tumors than in those with pancreatitis: they were elevated in 71.9% of the patients with pancreatic tumors. High CA 19-9 levels were found primarily in patients with a tumor of the head of the pancreas, in those with a tumor greater than 3 cm in its greatest diameter, and in those with an unresectable cancer. Only 57.1% of seven patients with a tumor of less than 3 cm in its greatest diameter showed an increase in CA 19-9 level. The CA 19-9 levels in pure pancreatic juice were significantly higher in patients with pancreatic tumors than in patients with pancreatitis without pancreatic stone. However, it was not useful for differentiating pancreatic tumors from pancreatitis with pancreatolithiasis. The CA 19-9 level in pancreatic materials obtained by aspiration biopsy was significantly higher in patients with malignant pancreatic tumors than in those with pancreatitis. Eight patients (80%) with pancreatic tumors had values above 1000 U/ml, whereas all five patients with pancreatitis had values of less than 30 U/ml. Although CA 19-9 levels in pancreatic materials was useful only when cytologic examination did not provide any evidence of malignancy, the combination of the CA 19-9 assay and the cytologic study of specimens obtained by percutaneous fine-needle aspiration biopsy of the pancreas increased the diagnostic rate to 100%.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3863691     DOI: 10.1002/1097-0142(19851201)56:11<2669::aid-cncr2820561124>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

Review 1.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

2.  Differences in plasma gastrin, CEA, and CA 19-9 concentration in patients with proximal and distal colorectal cancer.

Authors:  Grzegorz Bombski; Anita Gasiorowska; Daria Orszulak-Michalak; Beata Neneman; Justyna Kotynia; Janusz Strzelczyk; Adam Janiak; Ewa Malecka-Panas
Journal:  Int J Gastrointest Cancer       Date:  2002

Review 3.  Pancreatic cancer in 1988. Possibilities and probabilities.

Authors:  A L Warshaw; R S Swanson
Journal:  Ann Surg       Date:  1988-11       Impact factor: 12.969

4.  Monoclonal antibody to a human pancreatic carcinoma cell line recognizes gastrointestinal neoplasms.

Authors:  H J Kahn; H Yeger; R Loftus; M H Goldrosen
Journal:  Am J Pathol       Date:  1989-03       Impact factor: 4.307

Review 5.  Laboratory tests in the diagnosis of the chronic pancreatic diseases. Part 6. Differentiation between chronic pancreatitis and pancreatic cancer.

Authors:  E J Boyd; H Rinderknecht; K G Wormsley
Journal:  Int J Pancreatol       Date:  1988-05

Review 6.  Laboratory tests in the diagnosis of the chronic pancreatic diseases. Part 3. Tests on pure pancreatic juice.

Authors:  H Rinderknecht; E J Boyd; K G Wormsley
Journal:  Int J Pancreatol       Date:  1987 Oct-Dec

Review 7.  Imaging modalities for characterising focal pancreatic lesions.

Authors:  Lawrence Mj Best; Vishal Rawji; Stephen P Pereira; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-04-17

Review 8.  The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Authors:  Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill
Journal:  Curr Mol Med       Date:  2013-03       Impact factor: 2.222

9.  Elevated serum levels of tumor marker CA19-9 in acute cholangitis.

Authors:  M B Albert; W M Steinberg; J P Henry
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

10.  Enzyme-linked PNA lectin binding assay compared with CA19-9 and CEA radioimmunoassay as a diagnostic blood test for pancreatic cancer.

Authors:  C K Ching; J M Rhodes
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.